Prescription medication · NK1 Receptor Antagonist (Antiemetic)
rolapitant
Also sold as Varubi. Varubi is used to prevent delayed nausea and vomiting in adults.
Data updated 2026-05-15
- 531
- FDA reportsRarely reported
- 9
- InteractionsFew interactions
- Rx
- Availability
What the data shows
rolapitant (Varubi) is a prescription NK1 Receptor Antagonist (Antiemetic), among the least-reported drugs the FDA tracks (531 FDA reports), with 9 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
rolapitant (Varubi) is a prescription NK1 Receptor Antagonist (Antiemetic). Varubi is used to prevent delayed nausea and vomiting in adults.
Varubi is a medicine that helps prevent nausea and vomiting caused by chemotherapy. It is used with other anti-nausea medicines.
Verify with FDA → · CMS NADAC pricing →
What it does
Varubi is used to prevent delayed nausea and vomiting in adults.
Common side effects
Neutropenia (low white blood cell count), Hiccups, Abdominal pain
Key warnings
You should not take Varubi if you are taking thioridazine or pimozide.
The sections below are summarized in plain English from rolapitant's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Varubi blocks a substance in your body called substance P/neurokinin 1 (NK1). This substance can cause nausea and vomiting. By blocking it, Varubi helps prevent these side effects from chemotherapy.
Side Effects (from patient reports)
Based on 531 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for rolapitant, by number of reports
- Death
Death
141 reports
- Nausea
Nausea
79 reports
- Fatigue 50
Fatigue
50 reports
- Infusion Related Reaction 40
Infusion Related Reaction
40 reports
- Dyspnoea 34
Dyspnoea
34 reports
- Decreased Appetite 33
Decreased Appetite
33 reports
- Flushing 32
Flushing
32 reports
- Diarrhoea 29
Diarrhoea
29 reports
- Thrombocytopenia 29
Thrombocytopenia
29 reports
- Dehydration 22
Dehydration
22 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for rolapitant each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where rolapitant sits
rolapitant has more FDA adverse-event reports than 3% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is rolapitant; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 531 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
531
Reports Mentioning Death
161
30.3% of reports — not proof of cause
Hospitalization Reports
114
Top Indication
Nausea
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | DEATH | 141 |
| 2 | NAUSEA | 79 |
| 3 | FATIGUE | 50 |
| 4 | INFUSION RELATED REACTION | 40 |
| 5 | DYSPNOEA | 34 |
| 6 | DECREASED APPETITE | 33 |
| 7 | FLUSHING | 32 |
| 8 | DIARRHOEA | 29 |
| 9 | THROMBOCYTOPENIA | 29 |
| 10 | DEHYDRATION | 22 |
| 11 | VOMITING | 22 |
| 12 | CHEST DISCOMFORT | 21 |
| 13 | ANAEMIA | 20 |
| 14 | BACK PAIN | 19 |
| 15 | WEIGHT DECREASED | 17 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
You should not take Varubi if you are taking thioridazine or pimozide. These drugs can cause serious heart problems if taken with Varubi. Varubi can increase the levels of these drugs in your blood, leading to QT prolongation and Torsades de Pointes, which are dangerous heart rhythm problems.
Known Drug Interactions
Table 4: Clinically Relevant Interactions Affecting Drugs Co-Administered with VARUBI CYP2D6 Substrates Narrow Therapeutic Index Drugs (Thioridazine and Pimozide) Clinical Impact: Increased plasma concentrations of thioridazine and pimozide are associated with serious and/or life-threatening events of QT prolongation and Torsades de Pointes. Intervention: VARUBI is contraindicated in patients taking CYP2D6 substrates with a narrow therapeutic index such as thioridazine and pimozide. If patients require these drugs, use an alternative antiemetic to VARUBI or an alternative to thioridazine...
Mechanism: Rolapitant blocks the body from breaking down pimozide, which can lead to dangerously high levels of the drug in the blood. This buildup can cause serious or life-threatening heart rhythm problems.
Table 4: Clinically Relevant Interactions Affecting Drugs Co-Administered with VARUBI CYP2D6 Substrates Narrow Therapeutic Index Drugs (Thioridazine and Pimozide) Clinical Impact: Increased plasma concentrations of thioridazine and pimozide are associated with serious and/or life-threatening events of QT prolongation and Torsades de Pointes. Intervention: VARUBI is contraindicated in patients taking CYP2D6 substrates with a narrow therapeutic index such as thioridazine and pimozide. If patients require these drugs, use an alternative antiemetic to VARUBI or an alternative to thioridazine...
Mechanism: Rolapitant prevents the body from processing thioridazine, causing it to build up to unsafe levels. High levels of this drug can cause life-threatening heart rhythm issues.
rifampin) Clinical Impact: Co-administration of VARUBI with rifampin can significantly reduce the plasma concentrations of rolapitant and decrease the efficacy of VARUBI [see Clinical Pharmacology (12.3) ] . Strong CYP3A4 Inducers (e.g., rifampin) : significantly reduced plasma concentrations of rolapitant can decrease the efficacy of VARUBI; avoid use of VARUBI in patients who require chronic administration of such drugs.
Mechanism: Rifampin significantly lowers the levels of rolapitant in your blood. This makes the medication much less effective at preventing nausea and vomiting.
Use the lowest effective dose of rosuvastatin (see prescribing information for additional information on recommended dosing).
Mechanism: Rolapitant blocks a protein that helps clear rosuvastatin from your body, which can lead to higher levels of the statin in your blood.
Warfarin Clinical Impact: Although co-administration of intravenous rolapitant (VARBI is not approved for intravenous use), which has a higher C max than oral VARUBI, with warfarin did not substantially increase the systemic exposure to S-warfarin, the active enantiomer, the effects on INR and prothrombin time were not studied [see Clinical Pharmacology (12.3) ] . Intervention: Monitor INR and prothrombin time and adjust the dosage of warfarin, as needed with concomitant use of VARUBI, to maintain the target INR range. ( 7 ) Warfarin : Monitor for increased INR or prothrombin time; adjust...
Mechanism: It is not clear exactly how these drugs interact, but taking them together might change how well your blood thins.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I take Varubi if I am allergic to other anti-nausea medications?
Will Varubi interact with my other medications?
How long does Varubi stay in my system?
Can I drink alcohol while taking Varubi?
What should I do if I experience side effects from Varubi?
Does Varubi cure nausea and vomiting from chemotherapy?
Can I drive or operate machinery while taking Varubi?
Is Varubi safe for older adults?
How often will I take Varubi?
Can I split or crush the Varubi tablet?
What are the common side effects of rolapitant?
Does rolapitant interact with other medications?
What drug class is rolapitant?
What pregnancy or breastfeeding source fields are listed for rolapitant?
Related Medications in NK1 Receptor Antagonist (Antiemetic)
Other drugs grouped near rolapitant - same-class peers and common alternatives.
alosetron
Lotronex
Alosetron (Lotronex) is a medicine for women with severe diarrhea-predominant irritable bowel syndrome (IBS).
Compare with rolapitant →
aprepitant
Emend
Aprepitant (Emend) is a medicine that helps prevent nausea and vomiting.
Compare with rolapitant →
bisacodyl
Dulcolax
Bisacodyl is a medicine that helps you have a bowel movement.
Compare with rolapitant →
bismuth subsalicylate
Pepto-Bismol
Bismuth subsalicylate (Pepto-Bismol) is a medicine that can treat diarrhea and upset stomach.
Compare with rolapitant →
cimetidine
Tagamet
Cimetidine (Tagamet) reduces stomach acid.
Compare with rolapitant →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for rolapitant: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 531.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 30.32%.
- meropenem Δ 0.35 pts · 30,400 reports · Carbapenem Antibiotic 29.97%death share
- hydromorphone Δ 0.39 pts · 90,652 reports · Opioid Analgesic 30.71%death share
- ganciclovir Δ 0.40 pts · 9,877 reports · Antiviral (Nucleoside Analog) 30.72%death share
- aflibercept Δ 0.71 pts · 29,874 reports · Anti-VEGF (Ophthalmic Injection) 29.61%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on rolapitant
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for rolapitant
The FDA label for rolapitant (sold under brand names such as Varubi) classifies it as a prescription-only medication in the NK1 Receptor Antagonist (Antiemetic) class. Varubi is used to prevent delayed nausea and vomiting in adults. Official labeling lists 9 commonly reported side effects, including Neutropenia (low white blood cell count), Hiccups, Abdominal pain.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 531 voluntary reports. The database also lists 9 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: August 19, 2020
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages